GHRP-1
Overview
Growth Hormone Releasing Peptide-1 is a synthetic hexapeptide belonging to the growth hormone secretagogue family. It acts as a weak agonist at the ghrelin receptor (GHS-R1a) to stimulate pulsatile growth hormone release from the anterior pituitary.
Mechanism of Action
GHRP-1 has limited potency compared to later-generation secretagogues and served primarily as a prototype for subsequent drug development..
Research Summary & Key Findings
Early pharmacological studies in healthy volunteers demonstrated modest growth hormone release with reduced potency relative to GHRP-2 and GHRP-6. The compound has not advanced to pivotal clinical trials due to its limited efficacy and the availability of more potent analogs. It remains a research tool for studying growth hormone secretion pathways.
Clinical Status
GHRP-1 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
Related Peptides in Hormone
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...
View detailsIpamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...
View detailsSermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...
View detailsTesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...
View detailsFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply GHRP-1.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.